Trials / Recruiting
RecruitingNCT06298565
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 680 (estimated)
- Sponsor
- argenx · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | efgartigimod | efgartigimod |
Timeline
- Start date
- 2024-11-04
- Primary completion
- 2034-06-01
- Completion
- 2034-06-01
- First posted
- 2024-03-07
- Last updated
- 2026-02-17
Locations
35 sites across 6 countries: United States, Austria, Belgium, Germany, Italy, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06298565. Inclusion in this directory is not an endorsement.